CryoPort, Inc. (NASDAQ:CYRX – Get Free Report) Director Daniel Hancock sold 74,379 shares of the business’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $20.21, for a total transaction of $1,503,199.59. Following the transaction, the director owned 69,052 shares of the company’s stock, valued at approximately $1,395,540.92. The trade was a 51.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
CryoPort Price Performance
NASDAQ:CYRX opened at $19.89 on Friday. CryoPort, Inc. has a 12 month low of $7.61 and a 12 month high of $21.78. The firm has a market capitalization of $1.01 billion, a PE ratio of -20.50 and a beta of 1.89. The business’s fifty day moving average price is $17.43 and its 200 day moving average price is $13.70.
CryoPort (NASDAQ:CYRX – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The business had revenue of $50.22 million for the quarter, compared to analysts’ expectations of $48.66 million. CryoPort had a negative return on equity of 8.28% and a negative net margin of 21.46%. As a group, equities analysts anticipate that CryoPort, Inc. will post -0.88 EPS for the current year.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on CYRX shares. Piper Sandler raised CryoPort to a “buy” rating in a research report on Tuesday, October 13th. BTIG Research upped their price target on CryoPort from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Needham & Company LLC upped their price target on CryoPort from $19.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 6th. KeyCorp increased their price target on shares of CryoPort from $17.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 6th. Finally, Weiss Ratings raised shares of CryoPort from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, October 8th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, CryoPort has a consensus rating of “Moderate Buy” and an average target price of $21.69.
Check Out Our Latest Analysis on CryoPort
Hedge Funds Weigh In On CryoPort
Large investors have recently bought and sold shares of the stock. State of Alaska Department of Revenue acquired a new stake in shares of CryoPort during the third quarter worth about $40,000. State of Wyoming purchased a new stake in shares of CryoPort in the 3rd quarter valued at about $81,000. Counterpoint Mutual Funds LLC purchased a new stake in shares of CryoPort in the 3rd quarter valued at about $324,000. Highland Investment Advisors LLC purchased a new stake in shares of CryoPort in the 2nd quarter valued at about $306,000. Finally, Diversified Trust Co boosted its position in shares of CryoPort by 3.4% in the 3rd quarter. Diversified Trust Co now owns 19,769 shares of the company’s stock valued at $344,000 after purchasing an additional 657 shares during the period. Institutional investors and hedge funds own 92.90% of the company’s stock.
CryoPort Company Profile
Cryoport, Inc. provides temperature-controlled supply chain services for the life sciences industry. Its offerings support the development and commercial distribution of cell and gene therapies, biologics, reproductive medicine products and other temperature-sensitive materials. The company’s services include specialized shipping systems and packaging, transportation management, cryogenic storage, shipment monitoring and logistics support. These solutions are designed to help customers maintain required conditions and manage the handling of sensitive materials across clinical and commercial supply chains.
Featured Articles
- Five stocks we like better than CryoPort
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.
